Current portfolio
"Truth is born of arguments" - a beautiful humanistic motto of Locust (alias Mark Van Hoen) is a best audio illustration of pyramidal portfolio building.
Attention to all members: password to access website was changed to "password". Sorry for some problems with access.
Biotechs in current portfolio (long is blue and short-term investments are red):
NYMX
CARA (bought for long)
AKBA
EXEL
LXRX
OMER
NTLA
MESO
ARRY
MYGN
OSUR
NVO
NDRM
CYTK
IONS
PTCT
INCY
KPTI
AMRN
CERS
NVCR
AVEO
AUPH
VSTM (added more)
SRNE
ZFGN
INFI
ZIOP
BLCM
AIMT
GERN
IMMU (long)
ACST (long, Ph3 in Q4, 2019)
BiotechInvest credo: "Just give me a problem and I will try my best to solve it"
Each biotech company is a Challenge for investors. To solve this Challenge means to answer just one question: is this company technology/approaches/new drugs and etc. based the true scientific ideas or not? Each time when I want to invest money in biotech company I must to solve this Challenge. An Award for correct solving of Challenge is a big gain when this biotech company become successful. Incorrectly solved Challenge = huge losses.
Attention to all who are trying to "help your website to get on first page of Google and increase the number of leads and sales you are getting from your website. Please email us back for full proposal."
This website is non-commercial, it doesn't need "an increasing of number of leads", etc. Please, don't waste your time on writing "proposal e-mails" - such e-mails immediately go to spam box.
New services for 2018
Balanced biotech portfolio is always profitable and bring annual gain at least +25-35%. What is balanced portfolio? Is it possible to have it with $10k start money? How it should be changed when your $10k reached $50k? What if you have $100k for start?
In 2018 Biotech_Invest will start several paid services like:
1) evaluations of biotech company’s science basis (will allow to avoid money losses with scam biotechs and even make money on scam biotechs);
2) selection of biotech companies for portfolios ($10k-100k start money and up to $1-10M);
3) an evaluation of success probability of Ph3 clinical trials
Prices for each service are negotiable.